Skip to main content

Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Publication ,  Journal Article
Rizzieri, DA; Crout, C; Storms, R; Golob, J; Long, GD; Gasparetto, C; Sullivan, KM; Horwitz, M; Chute, J; Lagoo, AS; Morris, A; Beaven, A ...
Published in: Cancer Invest
January 2011

INTRODUCTION: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the feasibility of administering IL-2 following a T-cell-depleted nonmyeloablative hematopoietic stem cell transplant. METHODS: Patients received T-cell-depleted nonmyeloablative transplant from a matched or mismatched related donor. Those with allogeneic engraftment,

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

January 2011

Volume

29

Issue

1

Start / End Page

56 / 61

Location

England

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation Conditioning
  • Tissue Donors
  • Time Factors
  • Pilot Projects
  • Oncology & Carcinogenesis
  • North Carolina
  • Neoplasms
  • Myelodysplastic Syndromes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rizzieri, D. A., Crout, C., Storms, R., Golob, J., Long, G. D., Gasparetto, C., … Chao, N. J. (2011). Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. Cancer Invest, 29(1), 56–61. https://doi.org/10.3109/07357907.2010.535055
Rizzieri, David A., Christopher Crout, Robert Storms, Jared Golob, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, et al. “Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.Cancer Invest 29, no. 1 (January 2011): 56–61. https://doi.org/10.3109/07357907.2010.535055.
Rizzieri, David A., et al. “Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.Cancer Invest, vol. 29, no. 1, Jan. 2011, pp. 56–61. Pubmed, doi:10.3109/07357907.2010.535055.
Rizzieri DA, Crout C, Storms R, Golob J, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Lagoo AS, Morris A, Beaven A, Yang Y, Peterson B, Li Z, Chao NJ. Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. Cancer Invest. 2011 Jan;29(1):56–61.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

January 2011

Volume

29

Issue

1

Start / End Page

56 / 61

Location

England

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation Conditioning
  • Tissue Donors
  • Time Factors
  • Pilot Projects
  • Oncology & Carcinogenesis
  • North Carolina
  • Neoplasms
  • Myelodysplastic Syndromes